[go: up one dir, main page]

WO2007023298A3 - Anticorps - Google Patents

Anticorps Download PDF

Info

Publication number
WO2007023298A3
WO2007023298A3 PCT/GB2006/003187 GB2006003187W WO2007023298A3 WO 2007023298 A3 WO2007023298 A3 WO 2007023298A3 GB 2006003187 W GB2006003187 W GB 2006003187W WO 2007023298 A3 WO2007023298 A3 WO 2007023298A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
binds
antibody
fragment
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/003187
Other languages
English (en)
Other versions
WO2007023298A2 (fr
Inventor
Ming Lei
Bin Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of WO2007023298A2 publication Critical patent/WO2007023298A2/fr
Publication of WO2007023298A3 publication Critical patent/WO2007023298A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un anticorps ou un fragment de celui-ci qui se lie à une région extracellulaire formant un pore d'un canal ionique sodique. Les anticorps de l'invention peuvent être utilisés dans des méthodes de traitement.
PCT/GB2006/003187 2005-08-26 2006-08-25 Anticorps Ceased WO2007023298A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0517487.5A GB0517487D0 (en) 2005-08-26 2005-08-26 Antibodies
GB0517487.5 2005-08-26

Publications (2)

Publication Number Publication Date
WO2007023298A2 WO2007023298A2 (fr) 2007-03-01
WO2007023298A3 true WO2007023298A3 (fr) 2007-05-31

Family

ID=35198463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003187 Ceased WO2007023298A2 (fr) 2005-08-26 2006-08-25 Anticorps

Country Status (2)

Country Link
GB (1) GB0517487D0 (fr)
WO (1) WO2007023298A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6335152B2 (ja) * 2009-10-27 2018-05-30 ユセベ ファルマ ソシエテ アノニム イオンチャネルに対する抗体
CN102781963B (zh) * 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
SG10201601789TA (en) 2011-03-16 2016-04-28 Amgen Inc Potent And Selective Inhibitors Of Nav1.3 And Nav1.7
AR096927A1 (es) 2013-03-12 2016-02-10 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
WO2014165277A2 (fr) 2013-03-12 2014-10-09 Amgen Inc. Inhibiteurs sélectifs et puissants de nav1.7
KR20150127618A (ko) 2013-03-14 2015-11-17 리제너론 파아마슈티컬스, 인크. Nav1.7에 대한 사람 항체
FR3007762B1 (fr) 2013-06-28 2015-09-04 Galderma Res & Dev Anticorps diriges contre le canal sodique nav1.9 humain et leurs utilisations pour le diagnostic des maladies cutanees inflammatoires
FR3007763A1 (fr) * 2013-06-28 2015-01-02 Galderma Res & Dev Anticorps diriges contre le canal sodique nav1.9 humain et leurs utilisations en diagnostic
FR3007656B1 (fr) * 2013-06-28 2015-06-26 Galderma Res & Dev Modulateurs du canal sodique nav1.9 pour le traitement d'une maladie cutanee inflammatoire et methodes diagnostiques
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
NZ789594A (en) 2016-06-20 2025-07-25 Kymab Ltd Anti-PD-L1 antibodies
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
TWI841144B (zh) * 2022-12-26 2024-05-01 國立臺灣大學 標靶鈉離子通道的多株抗體、包含標靶鈉離子通道的多株抗體的醫藥組成物及其用於治療及/或預防心臟疾病的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573067B1 (en) * 1998-01-29 2003-06-03 Yale University Nucleic acid encoding sodium channels in dorsal root ganglia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573067B1 (en) * 1998-01-29 2003-06-03 Yale University Nucleic acid encoding sodium channels in dorsal root ganglia

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BRACKENBURY WJ, CHIONI A-M, DISS JKJ, DJAMGOZ MBA: "The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells", BREAST CANCER RES TREAT, vol. 101, 13 July 2006 (2006-07-13), pages 149 - 160, XP002415452 *
CHIONI ET AL: "A novel polyclonal antibody specific for the Nav1.5 voltage-gated Na<+> channel 'neonatal' splice form", JOURNAL OF NEUROSCIENCE METHODS, ELSEVIER SCIENCE PUBLISHER B.V., AMSTERDAM, NL, vol. 147, no. 2, 30 September 2005 (2005-09-30), pages 88 - 98, XP005047799, ISSN: 0165-0270 *
FRASER SCOTT P ET AL: "Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 AUG 2005, vol. 11, no. 15, 1 August 2005 (2005-08-01), pages 5381 - 5389, XP002415107, ISSN: 1078-0432 *
JULIE R GRALOW: "Optimizing the treatment of metastatic breast cancer", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 89, no. Suppl 1, 1 January 2005 (2005-01-01), pages S9 - S15, XP019274747, ISSN: 1573-7217 *
KRAFTE D S ET AL: "Stable expression and functional characterization of a human cardiac Na<+> channel gene in mammalian cells", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 27, no. 2, February 1995 (1995-02-01), pages 823 - 830, XP004537549, ISSN: 0022-2828 *
MAIER SEBASTIAN K G ET AL: "An unexpected role for brain-type sodium channels in coupling of cell surface depolarization to contraction in the heart.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 19 MAR 2002, vol. 99, no. 6, 19 March 2002 (2002-03-19), pages 4073 - 4078, XP002415110, ISSN: 0027-8424 *
THOMSEN W J ET AL: "Localization of the receptor site for alpha-scorpion toxins by antibody mapping: implications for sodium channel topology.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA DEC 1989, vol. 86, no. 24, December 1989 (1989-12-01), pages 10161 - 10165, XP002415108, ISSN: 0027-8424 *
XU SHANG-ZHONG ET AL: "Generation of functional ion-channel tools by E3 targeting.", NATURE BIOTECHNOLOGY OCT 2005, vol. 23, no. 10, October 2005 (2005-10-01), pages 1289 - 1293, XP002415111, ISSN: 1087-0156 *
YU FRANK H ET AL: "Overview of the voltage-gated sodium channel family.", GENOME BIOLOGY 2003, vol. 4, no. 3, 2003, pages 207, XP002415109, ISSN: 1465-6914 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain

Also Published As

Publication number Publication date
GB0517487D0 (en) 2005-10-05
WO2007023298A2 (fr) 2007-03-01

Similar Documents

Publication Publication Date Title
WO2007023298A3 (fr) Anticorps
WO2007008943A3 (fr) Proteines optimisees qui ciblent la molecule ep-cam
CY2018027I2 (el) Ανταγωνιστικα αντισωματα il-17
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
WO2006084264A3 (fr) Variants d&#39;anticorps et utilisations
IL206710A0 (en) Il-31 monoclonal antibodies
IL227753A0 (en) A qualified antibody or antibody residue
HUS1600037I1 (hu) Anti-IL-17 ellenanyagok
LT3421498T (lt) Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
SG10201404801YA (en) Monoclonal antibody
IL191617A (en) An antibody linked to polyubiquitin, a method for its preparation, a pharmaceutical preparation containing it and its uses
WO2012032181A3 (fr) Nouveaux dérivés d&#39;anticorps
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
SG170091A1 (en) Anti-5t4 antibodies and uses thereof
IL191600A0 (en) Antibody molecules having specificity for human il-6
PL1974017T5 (pl) Środki i sposoby do wpływania na stabilność komórek wytwarzających przeciwciała
WO2008048519A3 (fr) Anticorps se liant aux épitopes de cxcr7
MX2010001237A (es) Nuevos anticuerpos.
IL185781A0 (en) Antibodies against candida antigens
EP1860120A4 (fr) Procédé permettant d&#39;améliorer un anticorps
WO2006116319A3 (fr) Reactifs se liant au ccx-ckr2
WO2006100430A3 (fr) Polypeptides
WO2008140580A3 (fr) Sélection d&#39;anticorps spécifique par des conditions d&#39;élution sélective
WO2007002525A3 (fr) Anticorps de tomoreguline et leurs utilisations
WO2007002096A3 (fr) Methodes et compositions permettant de cibler ifnar2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06779218

Country of ref document: EP

Kind code of ref document: A2